|
1
|
Johnson LN: Protein kinase inhibitors:
Contributions from structure to clinical compounds. Q Rev Biophys.
42:1–40. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dy GK and Adjei AA: Understanding,
recognizing, and managing toxicities of targeted anticancer
therapies. CA Cancer J Clin. 63:249–279. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Christopoulos C, Dimakopoulou V and Rotas
E: Primary ovarian insufficiency associated with imatinib therapy.
N Engl J Med. 358:1079–1080. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Malozowski S, Nelson L and Calis KA: More
on ovarian insufficiency with imatinib. N Engl J Med. 358:26482008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schultheis B, Nijmeijer BA, Yin H, Gosden
RG and Melo JV: Imatinib mesylate at therapeutic doses has no
impact on folliculogenesis or spermatogenesis in a leukaemic mouse
model. Leuk Res. 36:271–274. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Asadi-Azarbaijani B, Santos RR,
Jahnukainen K, Braber S, van Duursen MBM, Toppari J, Saugstad OD,
Nurmio M and Oskam IC: Developmental effects of imatinib mesylate
on follicle assembly and early activation of primordial follicle
pool in postnatal rat ovary. Reprod Biol. 17:25–33. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sirotkin AV, Makarevich AV and Grosmann R:
Protein kinases and ovarian functions. J Cell Physiol. 226:37–45.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guo F, Kuo YF, Shih YCT, Giordano SH and
Berenson AB: Trends in breast cancer mortality by stage at
diagnosis among young women in the United States. Cancer.
124:3500–3509. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Richani D and Gilchrist RB: The epidermal
growth factor network: Role in oocyte growth, maturation and
developmental competence. Hum Reprod Update. 24:1–14. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Conti M, Hsieh M, Park JY and Su YQ: Role
of the epidermal growth factor network in ovarian follicles. Mol
Endocrinol. 20:715–723. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nagyova E, Nemcova L, Mlynarcikova A,
Scsukova S and Kalous J: Lapatinib inhibits meiotic maturation of
porcine oocyte-cumulus complexes cultured in vitro in
gonadotropin-supplemented medium. Fertil Steril. 99:1739–1748.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma Z, Parris AB, Xiao Z, Howard EW,
Kosanke SD, Feng X and Yang X: Short-term early exposure to
lapatinib confers lifelong protection from mammary tumor
development in MMTV-erbB-2 transgenic mice. J Exp Clin Cancer Res.
36:62017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Spector NL, Robertson FC, Bacus S,
Blackwell K, Smith DA, Glenn K, Cartee L, Harris J, Kimbrough CL,
Gittelman M, et al: Lapatinib plasma and tumor concentrations and
effects on HER receptor phosphorylation in tumor. PLoS One.
10:e01428452015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nelson JF, Felicio LS, Randall PK, Sims C
and Finch CE: A longitudinal study of estrous cyclicity in aging
C57BL/6J mice: I. Cycle frequency, length and vaginal cytology.
Biol Reprod. 27:327–339. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pedersen T and Peters H: Proposal for a
classification of oocytes and follicles in the mouse ovary. J
Reprod Fertil. 17:555–557. 1968. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Voigtlaender M, Schneider-Merck T and
Trepel M: Lapatinib. Recent Results Cancer Res. 211:19–44. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
da Rosa PRA, De Cesaro MP, Pereira Dau AM,
Duggavathi R, Bordignon V and Gonçalves PBD: Reversible meiotic
arrest of bovine oocytes by EGFR inhibition and follicular
hemisections. Theriogenology. 99:53–62. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ashkenazi H, Cao X, Motola S, Popliker M,
Conti M and Tsafriri A: Epidermal growth factor family members:
Endogenous mediators of the ovulatory response. Endocrinology.
146:77–84. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fan HY, Liu Z, Shimada M, Sterneck E,
Johnson PF, Hedrick SM and Richards JS: MAPK3/1 (ERK1/2) in ovarian
granulosa cells are essential for female fertility. Science.
324:938–941. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Siddappa D, Beaulieu É, Gévry N, Roux PP,
Bordignon V and Duggavathi R: Effect of the transient
pharmacological inhibition of Mapk3/1 pathway on ovulation in mice.
PLoS One. 10:e01193872015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Su YQ, Denegre JM, Wigglesworth K, Pendola
FL, O'Brien MJ and Eppig JJ: Oocyte-dependent activation of
mitogen-activated protein kinase (ERK1/2) in cumulus cells is
required for the maturation of the mouse oocyte-cumulus cell
complex. Dev Biol. 263:126–138. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sobinoff AP, Sutherland JM and Mclaughlin
EA: Intracellular signalling during female gametogenesis. Mol Hum
Reprod. 19:265–278. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Haraguchi S, Ikeda M, Akagi S and Hirao Y:
Dynamic changes in pStat3 are involved in meiotic spindle assembly
in mouse oocytes. Int J Mol Sci. 21:12202020. View Article : Google Scholar
|
|
24
|
Lee HS, Kim KH, Kim EY, Lee SY, Ko JJ and
Lee KA: Obox4-silencing-activated STAT3 and MPF/MAPK signaling
accelerate nuclear membrane breakdown in mouse oocytes.
Reproduction. 151:369–378. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tscherner A, Brown AC, Stalker L, Kao J,
Dufort I, Sirard MA and LaMarre J: STAT3 signaling stimulates
miR-21 expression in bovine cumulus cells during in vitro oocyte
maturation. Sci Rep. 8:115272018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zulkifli AA, Tan FH, Putoczki TL, Stylli
SS and Luwor RB: STAT3 signaling mediates tumour resistance to EGFR
targeted therapeutics. Mol Cell Endocrinol. 451:15–23. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dobi E, Monnien F, Kim S, Ivanaj A,
N'Guyen T, Demarchi M, Adotevi O, Thierry-Vuillemin A, Jary M,
Kantelip B, et al: Impact of STAT3 phosphorylation on the clinical
effectiveness of anti-EGFR-based therapy in patients with
metastatic colorectal cancer. Clin Colorectal Cancer. 12:28–36.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Haura EB, Sommers E, Song L, Chiappori A
and Becker A: A pilot study of preoperative gefitinib for
early-stage lung cancer to assess intratumor drug concentration and
pathways mediating primary resistance. J Thorac Oncol. 5:1806–1814.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Q, Zhang D, Chen X, He L, Li T, Xu X
and Li M: Nuclear PKM2 contributes to gefitinib resistance via
upregulation of STAT3 activation in colorectal cancer. Sci Rep.
5:160822015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bonner JA, Yang ES, Trummell HQ, Nowsheen
S, Willey CD and Raisch KP: Inhibition of STAT-3 results in greater
cetuximab sensitivity in head and neck squamous cell carcinoma.
Radiother Oncol. 99:339–343. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dowlati A, Nethery D and Kern JA: Combined
inhibition of epidermal growth factor receptor and JAK/STAT
pathways results in greater growth inhibition in vitro than single
agent therapy. Mol Cancer Ther. 3:459–463. 2004.PubMed/NCBI
|
|
32
|
Sen M, Joyce S, Panahandeh M, Li C, Thomas
SM, Maxwell J, Wang L, Gooding WE, Johnson DE and Grandis JR:
Targeting stat3 abrogates EGFR inhibitor resistance in cancer. Clin
Cancer Res. 18:4986–4996. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wen W, Wu J, Liu L, Tian Y, Buettner R,
Hsieh MY, Horne D, Dellinger TH, Han ES, Jove R and Yim JH:
Synergistic anti-tumor effect of combined inhibition of EGFR and
JAK/STAT3 pathways in human ovarian cancer. Mol Cancer. 14:1002015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ and
Settleman J: Drug resistance via feedback activation of Stat3 in
oncogene-addicted cancer cells. Cancer Cell. 26:207–221. 2014.
View Article : Google Scholar : PubMed/NCBI
|
